Continue reading this on our app for a better experience

Open in App
Home News Medtech

iX Biopharma launches sublingual dexmedetomidine wafer to treat agitation in dementia and other indications

The Editor
The Editor • 2 min read
iX Biopharma launches sublingual dexmedetomidine wafer to treat agitation in dementia and other indications
The global acute agitation and aggression treatment market size is projected to expand to US$7.09 billion by 2031 with a CAGR of 5.1% from 2021 to 2031.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.